Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'
Tweet Send to a Friend
H.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $425.00 (from $405.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
